Osteoporosis International

, Volume 30, Issue 2, pp 525–526 | Cite as

Correspondence in response to OSIN-D-18-00831 quantifying imminent risk

  • J.A. KanisEmail author
  • H. Johansson
  • N.C. Harvey
  • M. Lorentzon
  • E. Liu
  • F. Borgström
  • E.V. McCloskey


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Kanis JA, Johansson H, Odén A, Harvey NC, Gudnason V, Sanders K, Sigurdsson G, Siggeirsdottir K, Borgström F, McCloskey EV (2018) Characteristics of recurrent fractures. Osteoporos Int 29:1747–1757CrossRefGoogle Scholar
  2. 2.
    Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton IIILJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382CrossRefGoogle Scholar
  3. 3.
    Johansson H, Siggeirsdóttir K, Harvey NC, Odén A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775–780CrossRefGoogle Scholar
  4. 4.
    Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473CrossRefGoogle Scholar
  5. 5.
    Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fractures. Osteoporos Int 15:108–112CrossRefGoogle Scholar
  6. 6.
    Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl D, Cyrus Cooper C, on behalf of the IOF Working Group on Epidemiology and Quality of Life (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23:2239–2256CrossRefGoogle Scholar
  7. 7.
    Kanis JA, on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. Accessed 2 October 2018
  8. 8.
    Kanis JA, Harvey NC, Cooper C, Johansson H, Odén A, McCloskey EV (2016) A systematic review of intervention thresholds based on FRAX. Arch Osteoporos 11:25CrossRefGoogle Scholar
  9. 9.
    National Institute for Health and Care Excellence (2017) TA 464: Bisphosphonates for treating osteoporosis. Technology appraisal guidance 464. National Institute for Health and Care Excellence, London.
  10. 10.
    National Institute for Health and Care Excellence (2012) CG146: osteoporosis: fragility fracture risk. Short clinical guideline- evidence and recommendation, National Clinical Guideline Centre, LondonGoogle Scholar
  11. 11.
    Kanis JA, Cooper C, Rizzoli R, Reginster J-Y (2018) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int.
  12. 12.
    Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. CHMP, LondonGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2019

Authors and Affiliations

  1. 1.Centre for Metabolic Bone DiseasesUniversity of SheffieldSheffieldUK
  2. 2.Mary McKillop Health InstituteAustralian Catholic UniversityMelbourneAustralia
  3. 3.MRC Lifecourse Epidemiology UnitUniversity of SouthamptonSouthamptonUK
  4. 4.NIHR Southampton Biomedical Research CentreUniversity of Southampton and University Hospital Southampton NHS Foundation TrustSouthamptonUK
  5. 5.Geriatric Medicine, Department of Internal Medicine and Clinical Nutrition, Institute of MedicineUniversity of GothenburgGothenburgSweden
  6. 6.Geriatric MedicineSahlgrenska University HospitalMölndalSweden
  7. 7.LIME/MMCKarolinska InstitutetStockholmSweden
  8. 8.Mellanby Centre for Bone Research, Department of Oncology and MetabolismUniversity of SheffieldSheffieldUK

Personalised recommendations